Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Fulcrum Therapeutics initiates multi-center Phase 3 trial with losmapimod » 07:08
06/24/20
06/24
07:08
06/24/20
07:08
FULC

Fulcrum Therapeutics

$18.77 /

-0.36 (-1.88%)

Fulcrum Therapeutics…

Fulcrum Therapeutics announced that it received early notification from the U.S. Food and Drug Administration that the company may proceed with initiating a Phase 3, randomized, double-blind, placebo-controlled trial of losmapimod in higher risk hospitalized adults with COVID-19. Losmapimod is an orally available selective p38alpha/beta mitogen activated protein kinase inhibitor. The LOSVID trial is a Phase 3, international, multicenter trial designed to assess the safety and efficacy of a 15 mg twice per day oral dose of losmapimod compared to placebo for 14 days on top of standard of care in approximately 400 patients hospitalized with COVID-19 and at risk of progression to critical illness based on older age and elevated systemic inflammation. The primary endpoint is the proportion of patients who progress to death or respiratory failure by day 28. Additional secondary endpoints include clinical status on days seven and 14 as measured on the nine point WHO ordinal scale of COVID-19 severity, total number of study days free of oxygen supplementation, all-cause mortality, length of hospitalization and ICU stay, adverse events and viral clearance. An interim analysis will be conducted in the fourth quarter of 2020 for futility and sample size re-estimation by an independent data monitoring committee when approximately 50 percent of subjects complete the 28-day visit. Topline data is expected to be reported in the first quarter of 2021. Based on its mechanism of action and preclinical and clinical studies, Fulcrum believes that inhibiting the p38 MAPK pathway with losmapimod has the potential to treat COVID-19 by reducing the acute exaggerated pro-inflammatory responses to SARS-CoV-2 infection and restoring the antigen-specific immune responses needed for viral clearance potentially leading to improved clinical outcomes.

ShowHide Related Items >><<
FULC Fulcrum Therapeutics
$18.77 /

-0.36 (-1.88%)

FULC Fulcrum Therapeutics
$18.77 /

-0.36 (-1.88%)

06/19/20 BofA
Fulcrum Therapeutics downgraded to Neutral from Buy at BofA
06/19/20 BofA
Fulcrum Therapeutics downgraded to Neutral from Buy at BofA
06/17/20 Raymond James
Fulcrum Therapeutics upgraded to Outperform from Market Perform at Raymond James
06/16/20 BTIG
Fulcrum Therapeutics initiated with a Buy at BTIG
FULC Fulcrum Therapeutics
$18.77 /

-0.36 (-1.88%)

FULC Fulcrum Therapeutics
$18.77 /

-0.36 (-1.88%)

Syndicate
Fulcrum Therapeutics files to sell 4.03M shares of common stock for holders  16:18
06/22/20
06/22
16:18
06/22/20
16:18
FULC

Fulcrum Therapeutics

$19.13 /

-0.49 (-2.50%)

 
ShowHide Related Items >><<
FULC Fulcrum Therapeutics
$19.13 /

-0.49 (-2.50%)

FULC Fulcrum Therapeutics
$19.13 /

-0.49 (-2.50%)

06/19/20 BofA
Fulcrum Therapeutics downgraded to Neutral from Buy at BofA
06/19/20 BofA
Fulcrum Therapeutics downgraded to Neutral from Buy at BofA
06/17/20 Raymond James
Fulcrum Therapeutics upgraded to Outperform from Market Perform at Raymond James
06/16/20 BTIG
Fulcrum Therapeutics initiated with a Buy at BTIG
FULC Fulcrum Therapeutics
$19.13 /

-0.49 (-2.50%)

FULC Fulcrum Therapeutics
$19.13 /

-0.49 (-2.50%)

Downgrade
Fulcrum Therapeutics downgraded to Neutral from Buy at BofA » 06:20
06/19/20
06/19
06:20
06/19/20
06:20
FULC

Fulcrum Therapeutics

$20.50 /

+1.53 (+8.07%)

BofA analyst Tazeen Ahmad…

BofA analyst Tazeen Ahmad downgraded Fulcrum Therapeutics to Neutral from Buy with a higher price target of $23, up from $19. The stock price has appreciated to a level that is near full valuation relative to the stage of development of the company's "diverse" pipeline, the analyst tells investors in a research note. With a 35% probability of success for Losmapimod - up from 25% prior view - Ahmad models peak sales of $1.4B in 2030.

ShowHide Related Items >><<
FULC Fulcrum Therapeutics
$20.50 /

+1.53 (+8.07%)

FULC Fulcrum Therapeutics
$20.50 /

+1.53 (+8.07%)

06/19/20 BofA
Fulcrum Therapeutics downgraded to Neutral from Buy at BofA
06/17/20 Raymond James
Fulcrum Therapeutics upgraded to Outperform from Market Perform at Raymond James
06/16/20 BTIG
Fulcrum Therapeutics initiated with a Buy at BTIG
03/06/20 H.C. Wainwright
Fulcrum Therapeutics price target raised to $28 from $21 at H.C. Wainwright
FULC Fulcrum Therapeutics
$20.50 /

+1.53 (+8.07%)

FULC Fulcrum Therapeutics
$20.50 /

+1.53 (+8.07%)

Downgrade
Fulcrum Therapeutics downgraded to Neutral from Buy at BofA » 06:04
06/19/20
06/19
06:04
06/19/20
06:04
FULC

Fulcrum Therapeutics

$20.50 /

+1.53 (+8.07%)

BofA downgraded Fulcrum…

BofA downgraded Fulcrum Therapeutics to Neutral from Buy.

ShowHide Related Items >><<
FULC Fulcrum Therapeutics
$20.50 /

+1.53 (+8.07%)

FULC Fulcrum Therapeutics
$20.50 /

+1.53 (+8.07%)

06/17/20 Raymond James
Fulcrum Therapeutics upgraded to Outperform from Market Perform at Raymond James
06/16/20 BTIG
Fulcrum Therapeutics initiated with a Buy at BTIG
03/06/20 H.C. Wainwright
Fulcrum Therapeutics price target raised to $28 from $21 at H.C. Wainwright
12/24/19 H.C. Wainwright
Fulcrum 2020 data may support accelerated approval, says H.C. Wainwright
FULC Fulcrum Therapeutics
$20.50 /

+1.53 (+8.07%)

FULC Fulcrum Therapeutics
$20.50 /

+1.53 (+8.07%)

Upgrade
Fulcrum Therapeutics upgraded to Outperform from Market Perform at Raymond James » 07:50
06/17/20
06/17
07:50
06/17/20
07:50
FULC

Fulcrum Therapeutics

/

+

Raymond James analyst…

Raymond James analyst David Long upgraded Fulcrum Therapeutics to Outperform from Market Perform with a $12 price target.

ShowHide Related Items >><<
FULC Fulcrum Therapeutics
/

+

FULC Fulcrum Therapeutics
/

+

06/16/20 BTIG
Fulcrum Therapeutics initiated with a Buy at BTIG
03/06/20 H.C. Wainwright
Fulcrum Therapeutics price target raised to $28 from $21 at H.C. Wainwright
12/24/19 H.C. Wainwright
Fulcrum 2020 data may support accelerated approval, says H.C. Wainwright
10/03/19 H.C. Wainwright
Fulcrum Therapeutics initiated with a Buy at H.C. Wainwright
FULC Fulcrum Therapeutics
/

+

FULC Fulcrum Therapeutics
/

+

Initiation
Fulcrum Therapeutics initiated with a Buy at BTIG » 19:39
06/16/20
06/16
19:39
06/16/20
19:39
FULC

Fulcrum Therapeutics

$16.85 /

-0.2 (-1.17%)

BTIG analyst Dae Gon Ha…

BTIG analyst Dae Gon Ha initiated coverage of Fulcrum Therapeutics with a Buy rating and $27 price target. The company's lead asset - losmapimod - has the potential to become the first approved treatment for facioscapulohumeral muscular dystrophy, the analyst tells investors in a research note, adding that given the estimated prevalence of 16K-38K U.S. cases, he sees an attractive market opportunity with significant upside potential.

ShowHide Related Items >><<
FULC Fulcrum Therapeutics
$16.85 /

-0.2 (-1.17%)

FULC Fulcrum Therapeutics
$16.85 /

-0.2 (-1.17%)

03/06/20 H.C. Wainwright
Fulcrum Therapeutics price target raised to $28 from $21 at H.C. Wainwright
12/24/19 H.C. Wainwright
Fulcrum 2020 data may support accelerated approval, says H.C. Wainwright
10/03/19 H.C. Wainwright
Fulcrum Therapeutics initiated with a Buy at H.C. Wainwright
08/12/19 Morgan Stanley
Fulcrum Therapeutics initiated with an Overweight at Morgan Stanley
FULC Fulcrum Therapeutics
$16.85 /

-0.2 (-1.17%)

FULC Fulcrum Therapeutics
$16.85 /

-0.2 (-1.17%)

On The Fly
Fly Intel: Pre-market Movers » 09:03
06/10/20
06/10
09:03
06/10/20
09:03
GMAB

Genmab

$28.80 /

+0.37 (+1.30%)

, FULC

Fulcrum Therapeutics

$21.18 /

+1.19 (+5.95%)

, TRUE

TrueCar

$2.89 /

-0.085 (-2.86%)

, DUO

FangDD Network

$60.00 /

+50 (+500.00%)

, LAKE

Lakeland Industries

$20.80 /

+5.2 (+33.33%)

, UNFI

United Natural Foods

$22.40 /

-0.2 (-0.88%)

, RRGB

Red Robin

$17.01 /

-2.17 (-11.31%)

, CMCM

Cheetah Mobile

$3.45 /

+0.02 (+0.58%)

, GME

GameStop

$4.75 /

-0.25 (-5.00%)

, SBUX

Starbucks

$82.37 /

-1.22 (-1.46%)

, SALT

Scorpio Bulkers

$18.85 /

-5.84 (-23.65%)

, CSII

Cardiovascular Systems

$36.00 /

-5.29 (-12.81%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
UNFI United Natural Foods
$22.40 /

-0.2 (-0.88%)

TRUE TrueCar
$2.89 /

-0.085 (-2.86%)

SBUX Starbucks
$82.37 /

-1.22 (-1.46%)

SALT Scorpio Bulkers
$18.85 /

-5.84 (-23.65%)

RRGB Red Robin
$17.01 /

-2.17 (-11.31%)

LAKE Lakeland Industries
$20.80 /

+5.2 (+33.33%)

GME GameStop
$4.75 /

-0.25 (-5.00%)

GMAB Genmab
$28.80 /

+0.37 (+1.30%)

FULC Fulcrum Therapeutics
$21.18 /

+1.19 (+5.95%)

DUO FangDD Network
$60.00 /

+50 (+500.00%)

CSII Cardiovascular Systems
$36.00 /

-5.29 (-12.81%)

CMCM Cheetah Mobile
$3.45 /

+0.02 (+0.58%)

GMAB Genmab
$28.80 /

+0.37 (+1.30%)

06/03/20 Barclays
Genmab price target raised to DKK 2,150 from DKK 1,700 at Barclays
06/03/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Genmab, says ofatumumab delay not impactful
06/03/20 Bryan Garnier
Genmab downgraded to Neutral from Buy at Bryan Garnier
06/02/20 SunTrust
Genmab price target raised to $36 from $30 at SunTrust
FULC Fulcrum Therapeutics
$21.18 /

+1.19 (+5.95%)

03/06/20 H.C. Wainwright
Fulcrum Therapeutics price target raised to $28 from $21 at H.C. Wainwright
12/24/19 H.C. Wainwright
Fulcrum 2020 data may support accelerated approval, says H.C. Wainwright
10/03/19 H.C. Wainwright
Fulcrum Therapeutics initiated with a Buy at H.C. Wainwright
08/12/19 Morgan Stanley
Fulcrum Therapeutics initiated with an Overweight at Morgan Stanley
TRUE TrueCar
$2.89 /

-0.085 (-2.86%)

06/10/20 B. Riley FBR
B. Riley FBR upgrades TrueCar to Buy on improving auto trends
06/10/20 B. Riley FBR
TrueCar upgraded to Buy from Neutral at B. Riley FBR
03/13/20 Stephens
Stephens still sees 'decent chance' of TrueCar being acquired
02/21/20 Craig-Hallum
TrueCar price target lowered to $4 from $5 at Craig-Hallum
DUO FangDD Network
$60.00 /

+50 (+500.00%)

LAKE Lakeland Industries
$20.80 /

+5.2 (+33.33%)

06/10/20 Benchmark
Lakeland Industries price target raised to $31 after 'blow-out' at Benchmark
06/09/20 Benchmark
Benchmark starts PPE maker Lakeland Industries at Buy
06/09/20 Benchmark
Lakeland Industries initiated with a Buy at Benchmark
04/15/20 Roth Capital
Lakeland Industries resumed with a Buy at Roth Capital
UNFI United Natural Foods
$22.40 /

-0.2 (-0.88%)

05/15/20 BMO Capital
United Natural Foods price target raised to $22 from $10 at BMO Capital
05/13/20
Fly Intel: Top five analyst upgrades
05/13/20 Wells Fargo
United Natural Foods upgraded to Equal Weight on COVID benefits at Wells Fargo
05/13/20 Wells Fargo
United Natural Foods upgraded to Equal Weight from Underweight at Wells Fargo
RRGB Red Robin
$17.01 /

-2.17 (-11.31%)

02/26/20 Wells Fargo
Red Robin price target lowered to $30 from $35 at Wells Fargo
01/15/20 Maxim
Red Robin seeing early signs of turnaround, says Maxim
11/06/19 Loop Capital
Red Robin price target lowered to $33 from $36 at Loop Capital
09/05/19 Stephens
Red Robin back to 'trust me' story after takeover rejection, says Stephens
CMCM Cheetah Mobile
$3.45 /

+0.02 (+0.58%)

08/05/19 Jefferies
Cheetah Mobile initiated with an Underperform at Jefferies
06/17/19 Nomura Instinet
Cheetah Mobile price target loured to $3.60 from $7 at Nomura Instinet
GME GameStop
$4.75 /

-0.25 (-5.00%)

06/10/20 Baird
GameStop significant challenges remain ahead, says Baird
04/21/20 Baird
GameStop FY20 EPS target cut at Baird
03/27/20 Baird
GameStop trneds to remain weak despite recent increase, says Baird
03/20/20
Fly Intel: Top five analyst downgrades
SBUX Starbucks
$82.37 /

-1.22 (-1.46%)

06/09/20 BTIG
Beyond Meat's China distribution to accelerate sales in second half, says BTIG
05/28/20 Cleveland Research
Starbucks U.S. comp improvement to be moderate, says Cleveland Research
05/21/20 William Blair
Starbucks comps continuing to improve in both U.S. and China, says William Blair
05/21/20 Stephens
Starbucks tempered near-term expectations in update, says Stephens
SALT Scorpio Bulkers
$18.85 /

-5.84 (-23.65%)

04/20/20 BTIG
Scorpio Bulkers, Golden Ocean price targets cut at BTIG
02/04/20 Pareto
Scorpio Bulkers upgraded to Buy from Hold at Pareto
01/28/20 B. Riley FBR
Scorpio Bulkers price target lowered to $6.50 from $9.50 at B. Riley FBR
01/27/20 Fearnley
Scorpio Bulkers downgraded to Hold from Buy at Fearnley
CSII Cardiovascular Systems
$36.00 /

-5.29 (-12.81%)

05/06/20 Lake Street
Cardiovascular Systems price target lowered to $48 from $54 at Lake Street
04/06/20 Oppenheimer
Cardiovascular Systems initiated with an Outperform at Oppenheimer
04/03/20 Lake Street
Cardiovascular Systems price target lowered to $54 from $60 at Lake Street
10/18/19 Guggenheim
Guggenheim starts 'underestimated' Cardiovascular Systems at Buy
UNFI United Natural Foods
$22.40 /

-0.2 (-0.88%)

TRUE TrueCar
$2.89 /

-0.085 (-2.86%)

SBUX Starbucks
$82.37 /

-1.22 (-1.46%)

SALT Scorpio Bulkers
$18.85 /

-5.84 (-23.65%)

RRGB Red Robin
$17.01 /

-2.17 (-11.31%)

LAKE Lakeland Industries
$20.80 /

+5.2 (+33.33%)

GME GameStop
$4.75 /

-0.25 (-5.00%)

GMAB Genmab
$28.80 /

+0.37 (+1.30%)

FULC Fulcrum Therapeutics
$21.18 /

+1.19 (+5.95%)

DUO FangDD Network
$60.00 /

+50 (+500.00%)

CSII Cardiovascular Systems
$36.00 /

-5.29 (-12.81%)

CMCM Cheetah Mobile
$3.45 /

+0.02 (+0.58%)

  • 10
    Jun
  • 10
    Jun
SBUX Starbucks
$82.37 /

-1.22 (-1.46%)

LAKE Lakeland Industries
$20.80 /

+5.2 (+33.33%)

GME GameStop
$4.75 /

-0.25 (-5.00%)

CMCM Cheetah Mobile
$3.45 /

+0.02 (+0.58%)

UNFI United Natural Foods
$22.40 /

-0.2 (-0.88%)

TRUE TrueCar
$2.89 /

-0.085 (-2.86%)

SBUX Starbucks
$82.37 /

-1.22 (-1.46%)

SALT Scorpio Bulkers
$18.85 /

-5.84 (-23.65%)

RRGB Red Robin
$17.01 /

-2.17 (-11.31%)

LAKE Lakeland Industries
$20.80 /

+5.2 (+33.33%)

GME GameStop
$4.75 /

-0.25 (-5.00%)

CSII Cardiovascular Systems
$36.00 /

-5.29 (-12.81%)

CMCM Cheetah Mobile
$3.45 /

+0.02 (+0.58%)

UNFI United Natural Foods
$22.40 /

-0.2 (-0.88%)

SBUX Starbucks
$82.37 /

-1.22 (-1.46%)

RRGB Red Robin
$17.01 /

-2.17 (-11.31%)

LAKE Lakeland Industries
$20.80 /

+5.2 (+33.33%)

GME GameStop
$4.75 /

-0.25 (-5.00%)

Conference/Events
Fulcrum Therapeutics holds a conference call » 07:55
06/10/20
06/10
07:55
06/10/20
07:55
FULC

Fulcrum Therapeutics

$21.18 /

+1.19 (+5.95%)

Management discusses…

Management discusses evaluating Losmapimod as a potential treatment for COVID-19 on a conference call to be held on June 10 at 8:30 am. Webcast Link

ShowHide Related Items >><<
FULC Fulcrum Therapeutics
$21.18 /

+1.19 (+5.95%)

FULC Fulcrum Therapeutics
$21.18 /

+1.19 (+5.95%)

03/06/20 H.C. Wainwright
Fulcrum Therapeutics price target raised to $28 from $21 at H.C. Wainwright
12/24/19 H.C. Wainwright
Fulcrum 2020 data may support accelerated approval, says H.C. Wainwright
10/03/19 H.C. Wainwright
Fulcrum Therapeutics initiated with a Buy at H.C. Wainwright
08/12/19 Morgan Stanley
Fulcrum Therapeutics initiated with an Overweight at Morgan Stanley
FULC Fulcrum Therapeutics
$21.18 /

+1.19 (+5.95%)

Hot Stocks
Fulcrum Therapeutics expects cash to fund requirements into 1Q22 » 07:06
06/10/20
06/10
07:06
06/10/20
07:06
FULC

Fulcrum Therapeutics

$21.18 /

+1.19 (+5.95%)

The Company expects that…

The Company expects that its cash, cash equivalents, and marketable securities of $81.2M as of March 31, 2020, together with the $68.5M in gross proceeds from its private placement, will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2022.

ShowHide Related Items >><<
FULC Fulcrum Therapeutics
$21.18 /

+1.19 (+5.95%)

FULC Fulcrum Therapeutics
$21.18 /

+1.19 (+5.95%)

03/06/20 H.C. Wainwright
Fulcrum Therapeutics price target raised to $28 from $21 at H.C. Wainwright
12/24/19 H.C. Wainwright
Fulcrum 2020 data may support accelerated approval, says H.C. Wainwright
10/03/19 H.C. Wainwright
Fulcrum Therapeutics initiated with a Buy at H.C. Wainwright
08/12/19 Morgan Stanley
Fulcrum Therapeutics initiated with an Overweight at Morgan Stanley
FULC Fulcrum Therapeutics
$21.18 /

+1.19 (+5.95%)

Hot Stocks
Fulcrum Therapeutics to evaluate losmapimod as COVID-19 treatment » 07:05
06/10/20
06/10
07:05
06/10/20
07:05
FULC

Fulcrum Therapeutics

$21.18 /

+1.19 (+5.95%)

Fulcrum Therapeutics…

Fulcrum Therapeutics announced plans to evaluate losmapimod as a potential treatment for patients with COVID-19. Fulcrum has submitted an investigational new drug application to support initiation of a randomized, placebo-controlled, Phase 3 clinical trial in hospitalized patients in the United States following Pre-IND consultation via the Coronavirus Treatment Acceleration Program. Several lines of preclinical and clinical evidence indicate that activation of the p38 mitogen-activated protein kinase significantly contributes to the pathogenesis of coronavirus infections including COVID-19. p38 MAPK is well known as an important mediator of acute response to stress, including acute inflammation. In two clinical studies reported in the literature, an oral dose of 15 mg twice per day of losmapimod in older individuals restored the normal immune response to a viral antigen challenge and demonstrated resolution of acute inflammation, a relevant observation because the majority of severe and fatal cases of COVID-19 occur in older individuals. Additionally, in prior human clinical trials predominantly in chronic inflammatory conditions, losmapimod had an immediate effect on a number of inflammatory biomarkers that have been associated with poor prognosis in COVID-19, including C-reactive protein and interleukin-6. In previous trials in more than 3,600 subjects, losmapimod exhibited favorable safety and tolerability not significantly different from placebo. These trials have also indicated that losmapimod had good exposure after oral dosing and robust target engagement. The Company believes that losmapimod has the potential to treat COVID-19 by reducing the acute exaggerated pro-inflammatory responses to SARS-CoV-1 infection and restoring the antigen-specific immune responses needed for clearance of SARS-CoV-2, potentially leading to improved clinical outcomes. Additionally, p38 inhibition has been demonstrated to reduce angiotensin II-induced endothelial and organ damage in several experimental models and may address the renin-angiotensin system imbalance that is believed to contribute to key morbidities in COVID-19 patients.

ShowHide Related Items >><<
FULC Fulcrum Therapeutics
$21.18 /

+1.19 (+5.95%)

FULC Fulcrum Therapeutics
$21.18 /

+1.19 (+5.95%)

03/06/20 H.C. Wainwright
Fulcrum Therapeutics price target raised to $28 from $21 at H.C. Wainwright
12/24/19 H.C. Wainwright
Fulcrum 2020 data may support accelerated approval, says H.C. Wainwright
10/03/19 H.C. Wainwright
Fulcrum Therapeutics initiated with a Buy at H.C. Wainwright
08/12/19 Morgan Stanley
Fulcrum Therapeutics initiated with an Overweight at Morgan Stanley
FULC Fulcrum Therapeutics
$21.18 /

+1.19 (+5.95%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.